For patients with advanced non-squamous non-small cell lung cancer (NSCLC) who lack sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) gene rearrangements, platinum-based doublet chemotherapy regimens, such as pemetrexed plus cisplatin (Pem-Cis), are currently recommended.[1] Superior efficacy and reduced toxicity has been reported for Pem-Cis, in comparison to other chemotherapy regimens. The gene discussed is ALK; the disease is non-small cell lung carcinoma.